Industrializing allogeneic iPSC-derived cell therapies: challenges and solutions

Induced pluripotent stem cell (iPSC) technology has opened new opportunities to develop novel therapies consisting of cells of almost any type such as neurons, cardiomyocytes, beta islet cells, T or NK cells, mesenchymal stromal cells, and many others. These have the potential to slow or halt the progression of a broad range of degenerative diseases or even restore lost organ function. Over the last 10 years, these therapies have progressed into clinical efficacy trials, and the first major products are approaching market approval. As the global Industry pipeline continues to expand and mature, the need for efficient scaling, high output, and acceptable cost of goods requires new technical solutions. Every stage in the manufacture of an iPSC-derived cell therapy presents its own distinct challenges, ranging from the choice of the iPS cell line to iPSC amplification, differentiation into target cells at a high degree of purity and at the required quality, amplification, formulation, filling and packaging of the final cell product, and cold chain logistics to the point of care, where national regulation needs to be observed regarding the preparation of the injectable dose and its administration to the patient. Various technologies reducing shear stress, robotics, automation, and integration are emerging to debottleneck capacity limitations, making the process consistent, and lowering cost of goods.

Manual iPSC manufacturing processes limit the scalability and affordability of allogeneic cell therapies. This article examines the bottlenecks at each production stage and the technologies being developed to overcome them.

What you will learn

01

Why iPSCs offer key advantages over donor-derived cells for consistent, scalable manufacturing

02

Where the critical bottlenecks lie across the iPSC manufacturing pathway

03

How robotics and novel reactor technologies are enabling commercial-scale output

The iPSC manufacturing pathway

1

iPSC expansion

2

Differentiation

3

Cell amplification

4

Fill & finish

5

Cryopreservation & distribution

Key findings

Differentiation is the critical bottleneck — manual, multi-step protocols are incompatible with the output required for commercial-scale demand

Robotic automation and shear-stress-reducing bioreactor technologies are the primary path to consistent, high-volume output

Affordable cost of goods requires advances across the full process — from cell amplification and QC to cold chain and last-mile delivery

Key interests

iPSCs

Cell Therapy

Manufacturing Scale-up

Automation

Regenerative Medicine

Read the full article below